论文部分内容阅读
美国华纳兰伯特公司预期1997年后期将为舒拉明钠(ｓｕｒａｍｉｎｓｏｄｉｕｍ,ＥＮ116051)用于治疗前列腺癌递交新药注册申请。药理作用 舒拉明完全抑制凝血酶诱导的血纤维蛋白形成,是因为该药具有与血纤维蛋白单体形成可溶性和不可凝复合物的能力。该药通过阻止胰岛素样生长
Warner Lambert expects to file a request for registration of a new drug for the treatment of prostate cancer in late 1997 in the country of suraminsodium (EN116051). Pharmacological effects Shuremine completely inhibits thrombin-induced fibrin formation because of its ability to form soluble and non-condensable complexes with fibrin monomers. The drug works by blocking insulin-like growth